| Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration | Diabetes Therapy | 2 days | save |  |  |  |  |
| Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus | Diabetes Therapy | 3 days | save | | | | |
| Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review | Diabetes Therapy | 4 days | save | | | | |
| A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan | Diabetes Therapy | 5 days | save | | | | |
| Correction to: Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas | Diabetes Therapy | 7 days | save | | | | |
| Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes | Diabetes Therapy | 8 days | save | | | | |
| Effect of Baseline Characteristics on Hypoglycaemia Risk with Insulin Glargine 100 U/mL: Post Hoc Analysis of the BEYOND 7 Study | Diabetes Therapy | 9 days | save | | | | |
| Factors Associated With Treatment Adherence and Satisfaction in Type 2 Diabetes Management in Japan: Results From a Web-Based Questionnaire Survey | Diabetes Therapy | 10 days | save | | | | |
| Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States | Diabetes Therapy | 11 days | save | | | | |
| Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs) | Diabetes Therapy | 14 days | save | | | | |
| Correction to: Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population | Diabetes Therapy | 21 days | save | | | | |
| The Impact of COVID-19 Lockdown on Metabolic Control and Access to Healthcare in People with Diabetes: the CONFI-DIAB Cross-Sectional Study | Diabetes Therapy | 21 days | save | | | | |
| The Impact of Different Insulin-Related Measures on the Risk of Prediabetes Among the Chinese Han Population | Diabetes Therapy | 22 days | save | | | | |
| Analysis Estimating the Potential Cost Impact of Utilizing Flash Glucose Monitoring with Optional Alarms in Swedish Adults with Diabetes with Impaired Awareness of Hypoglycaemia, Using Intensive Insulin | Diabetes Therapy | 23 days | save | | | | |
| Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study | Diabetes Therapy | 26 days | save | | | | |
| Differential Cost-Sharing Undermines Treatment Adherence to Combination Therapy: Evidence from Diabetes Treatment | Diabetes Therapy | 29 days | save | | | | |
| Impact of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Randomised Multicentre Study | Diabetes Therapy | 37 days | save | | | | |
| Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study | Diabetes Therapy | 37 days | save | | | | |
| A Claims-Based Cohort Study on the Treatment Patterns of Japanese Patients with Type 2 Diabetes Mellitus and the Association of Early First Physician Visit with Time to Prescription of Oral Hypoglycemic Agents | Diabetes Therapy | 40 days | save | | | | |
| Improvements in Glycemic Control Achieved by Altering the tmax Setting in the iLet® Bionic Pancreas When Using Fast-Acting Insulin Aspart: A Randomized Trial | Diabetes Therapy | 41 days | save | | | | |
| Electronic Medical Record Risk Modeling of Cardiovascular Outcomes Among Patients with Type 2 Diabetes | Diabetes Therapy | 42 days | save | | | | |
| Pill Counting in the Determination of Factors Affecting Medication Adherence in Patients with Type 2 Diabetes: A Retrospective Observational Study | Diabetes Therapy | 47 days | save | | | | |
| Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study | Diabetes Therapy | 48 days | save | | | | |
| Treatment Patterns, Effectiveness, and Satisfaction Among Patients with Type 2 Diabetes Treated with Insulin in Saudi Arabia: Results of the RIMODIS Study | Diabetes Therapy | 49 days | save | | | | |
| Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand | Diabetes Therapy | 51 days | save | | | | |
| The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics | Diabetes Therapy | 53 days | save | | | | |
| Episodic Real-Time CGM Use in Adults with Type 2 Diabetes: Results of a Pilot Randomized Controlled Trial | Diabetes Therapy | 55 days | save | | | | |
| Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation | Diabetes Therapy | 57 days | save | | | | |
| Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis | Diabetes Therapy | 58 days | save | | | | |
| A Guideline-Based Decision Tree Achieves Better Glucose Control with Less Hypoglycemia at 3 Months in Chinese Diabetic Patients | Diabetes Therapy | 62 days | save | | | | |
| The Role of Finerenone in the Management of Diabetic Nephropathy | Diabetes Therapy | 62 days | save | | | | |
| Diabetes Therapy Podcast Collection: Language Matters in Diabetes | Diabetes Therapy | 63 days | save | | | | |
| Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus | Diabetes Therapy | 63 days | save | | | | |
| The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective | Diabetes Therapy | 64 days | save | | | | |
| Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review | Diabetes Therapy | 65 days | save | | | | |
| Prospective Independent Evaluation of the Carbohydrate Counting Accuracy of Two Smartphone Applications | Diabetes Therapy | 67 days | save | | | | |
| Insulin Management of Patients with Inadequately Controlled Type 2 Diabetes Admitted to Hospital: Titration Patterns and Frequency of Hypoglycemia as Results of a Prospective Observational Study (Hospital Study) | Diabetes Therapy | 67 days | save | | | | |
| Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM | Diabetes Therapy | 71 days | save | | | | |
| Correction to: Injection Technique Education in Patients with Diabetes Injecting Insulin into Areas of Lipohypertrophy: A Randomized Controlled Trial | Diabetes Therapy | 73 days | save | | | | |
| Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis | Diabetes Therapy | 73 days | save | | | | |
| Risk Prediction Model of Gestational Diabetes Mellitus in a Chinese Population Based on a Risk Scoring System | Diabetes Therapy | 75 days | save | | | | |
| Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas | Diabetes Therapy | 78 days | save | | | | |
| Favorable Effects of 24‐Week Whole-Body Vibration on Glycemic Control and Comprehensive Diabetes Therapy in Elderly Patients with Type 2 Diabetes | Diabetes Therapy | 79 days | save | | | | |
| Descriptive Regional Subanalysis of a Real-World Study in Patients with Type 2 Diabetes Treated with Gliclazide MR During Fasting: DIA-RAMADAN | Diabetes Therapy | 80 days | save | | | | |
| Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population | Diabetes Therapy | 86 days | save | | | | |
| New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications? | Diabetes Therapy | 87 days | save | | | | |
| Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review | Diabetes Therapy | 87 days | save | | | | |
| Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study | Diabetes Therapy | 90 days | save | | | | |
| One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus | Diabetes Therapy | 91 days | save | | | | |
| Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes | Diabetes Therapy | 92 days | save | | | | |
| | 
report | next » |
| |
